Exelixis Company
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.
Connections from
Estimated Revenue:
$100M to $500M
Funding Status:
IPO
Industry:
Genomic and Epigenominc Instabillity
Technology:
Neurological Disorders
Founded Date:
1994
Headquarters:
United States
Employee Number:
251-500